Immunomedics has licensed its proprietary method of labeling antibodies with technetium-99m (Tc-99m) to Agen Biomedical, and is looking for other licensing opportunities.
The Morris Plains, NJ, firm said Agen, of Brisbane, Australia, will use the labeling method with a clot imaging agent it is developing. The agent involves a humanized antibody linked to a determinant expressed on deep vascular clots and pulmonary emboli, and is being developed for detection of those two disease states.
Immunomedics' method allows nuclear medicine physicians to directly label the antibody a few minutes before it is administered to patients. Patients can then be imaged with standard gamma cameras to reveal sites of trapped clots in the body.
Immunomedics president and CEO Cynthia Sullivan said the company welcomes opportunities to license its patent portfolio on a nonexclusive basis.
By AuntMinnie.com staff writers
October 29, 2001
Related Reading
Immunomedics trims loss in 2001, August 8, 2001
Immunomedics appoints Sullivan CEO, March 21, 2001
Copyright © 2001AuntMinnie.com
